Novartis: Pioneering Advances in Immunology and Oncology

Novartis AG is a global pharmaceutical leader dedicated to discovering, developing, and marketing innovative medicines. As of 2025, the company’s therapeutic areas include oncology, immunology, cardiovascular, renal and metabolic diseases, and neuroscience. Novartis also engages in the subcontracted manufacturing of pharmaceutical products, operating over 31 production sites worldwide.

A Focus on Immunology: Targeting Autoimmune Diseases

Novartis is significantly invested in immunology, representing 18.9% of its turnover. The company is focused on advancing scientific understanding and developing treatments for autoimmune diseases, which often present diagnostic challenges and significantly impact patients’ quality of life. Research efforts are concentrated in dermatology, allergy, and rheumatology, aiming to address areas where therapeutic progress has been limited.

Key areas of focus within immunology include:

• Chronic spontaneous urticaria (CSU)
• Sjogren’s disease (SjD)
• Hidradenitis suppurativa
• Plaque psoriasis
• Psoriatic arthritis
• Axial spondyloarthritis

Novartis recognizes the complex nature of autoimmune conditions like Sjogren’s disease, which affects up to 4 million people in the U.S., predominantly women, and can impact multiple organ systems beyond the commonly recognized symptoms of dry eyes and dry mouth.

Revolutionizing Cancer Care Through Oncology Research

Oncology constitutes 30.9% of Novartis’s revenue, making it a core strategic area. The company is reimagining cancer care through radioligand therapy (RLT), a form of precision nuclear medicine. Novartis’s oncology research focuses on:

• Breast cancer
• Prostate cancer
• Lung cancer
• Chronic myeloid leukemia (CML)
• Neuroendocrine tumors (NETs)

Novartis is committed to improving patient access to clinical trials, identifying new disease pathways, and developing therapies to extend and improve the lives of those affected by cancer. Significant progress has been made in treating CML, but ongoing research aims to address resistance and intolerance to existing therapies.

Global Presence and Financial Overview

Novartis maintains a substantial global presence, with its turnover distributed as follows:

• Switzerland: 2.6%
• Europe: 28.1%
• United States: 42.8%
• Asia, Africa, Australasia: 19.8%
• Canada and Latin America: 6.7%

Looking Ahead

Novartis continues to invest in research and development across its key therapeutic areas, aiming to deliver innovative medicines and improve patient outcomes worldwide. The company’s commitment to scientific advancement and collaboration positions it as a leader in the pharmaceutical industry.